N-SUBSTITUTED PHTHALIMIDINES

Compounds of formula (I) and pharmaceutically acceptable salt and/or solvates and/or N-oxides thereof: wherein R2 and R3 are the same or different and are hydrogen, halogen, CF3, C1-6 alkyl, C1-7 acyl, C1-7 acylamino or amino, aminocarbonyl or aminosulphonyl optionally substituted by one or two C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl, C1-4 alkyl, phenyl or phenyl C1-4 alkyl groups either of which phenyl moieties may be substituted by one or more halogen, trifluoromethyl, C1-6 alkoxy or nitro groups or N-substituted by C4-5 polymethylene, C1-6 alkylsulphonyl, C1-6 alkylsulphinyl, C1-6 alkoxy C1-6 alkylthio; hydroxy or nitro; or R2 and R3 taken together are methylenedioxy or ethylenedioxy; R4 is C1-7 alkyl or a group -(CH2)sR6 where s is 0 to 2 and R6 is a C3-8 cycloalkyl group, or a group -(CH2)tR7 where t is 1 or 2 and R7 is a phenyl group optionally substituted by one or two substituents selected from C1-4 alkoxy, trifluoromethyl and halogen, carboxy, esterified carboxy, or C1-4 alkyl optionally substituted by hydroxy, C1-4 alkoxy in vivo hydrolysable acyloxy, carboxy, or esterified carboxy; or a thienyl group; p and q are independently 0 to 2; and r is 1 or 2. having dopamine antagonist activity, a process to their preparation and their use.